Dan Gelvan - Vascular Biogenics Non-Executive Independent Director

VBLTDelisted Stock  USD 0.16  0.01  5.88%   

Director

Dr. Dan J. Gelvan serves as NonExecutive Independent Director at Vascular Biogenics Ltd since July 2005. He is a member of the audit committee. Dr. Gelvan work experience includes the following roles Managing DirectorLife Sciences of Aurum Ventures M.K.I Ltd, Chief Executive and President of GammaCan International, Inc., member of the Israel National Committee on Biotechnology, Chief Executive Officer and President of Zetiq Technologies and he has held senior roles at Clal Insurance Enterprises Holdings Ltd since 2005.
Age 50
Tenure 19 years
Phone972 8 993 5000
Webhttps://www.vblrx.com
Gelvan holds a Bachelors degree in Economics and a Masters degree in Economics, both from The Hebrew University of Jerusalem and a Doctorate in Philosophy degree in Business Economics from Roskilde University, Denmark.

Vascular Biogenics Management Efficiency

The company has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 564 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Vascular Biogenics has a current ratio of 3.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vascular Biogenics until it has trouble settling it off, either with new capital or with free cash flow. So, Vascular Biogenics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vascular Biogenics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vascular to invest in growth at high rates of return. When we think about Vascular Biogenics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Robert LynchKontoor Brands
44
William JordanRocky Brands
45
David WarnockPrimo Water Corp
60
Michael FinnRocky Brands
70
Gene HaningRocky Brands
65
Susan CatesPrimo Water Corp
49
Anthony DeeringUnder Armour A
71
David GibbsUnder Armour A
57
Robert MooreRocky Brands
66
Mark SchillerKontoor Brands
59
George BodenheimerUnder Armour A
60
Byron AdamsUnder Armour A
60
Harvey SandersUnder Armour A
71
Glenn CorlettRocky Brands
73
G HaningRocky Brands
65
Karen KatzUnder Armour A
64
Richard BrennerPrimo Water Corp
54
Kathy WallerMonster Beverage Corp
58
James StewartRocky Brands
80
Benjamin PolkMonster Beverage Corp
66
Westley MooreUnder Armour A
42
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. Vascular Biogenics (VBLT) is traded on NASDAQ Exchange in USA and employs 7 people.

Management Performance

Vascular Biogenics Leadership Team

Elected by the shareholders, the Vascular Biogenics' board of directors comprises two types of representatives: Vascular Biogenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vascular. The board's role is to monitor Vascular Biogenics' management team and ensure that shareholders' interests are well served. Vascular Biogenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vascular Biogenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Dror Harats, CEO, Director
Amos Ron, CFO
Samuel Backenroth, Chief Officer
Bennett Shapiro, Non-Executive Independent Chairman of the Board
Naamit Sher, VP of Devel. and Regulatory
Ayelet Horn, General Counsel, Company Secretary
Philip Serlin, Non-Executive Independent Director
Dan Gelvan, Non-Executive Independent Director
Eyal Breitbart, Vice President Research
Ron Cohen, Non-Executive Independent Director
Pr MD, CEO Director
Tami MD, VP Devel
Ruth Alon, Non-Executive Independent Director
Erez Feige, Vice President - Business Operations
Ruth Arnon, Non-Executive Independent Director
Yael Cohen, Vice President - Clinical Development
Erez MBA, Sr Operations
Jacob George, Chief Scientific Officer
Jecheskiel Gonczarowski, Non-Executive Independent Director
Deborah Scott, Managing Communications
Jide Zeitlin, Non-Executive Independent Director
Advocate Horn, G Counsel

Vascular Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vascular Biogenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Consideration for investing in Vascular Stock

If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
FinTech Suite
Use AI to screen and filter profitable investment opportunities